538 Correlation Between Adalimumab Serum Levels and Remission After the Induction Phase in Crohn's Disease Patients

MLA

María Chaparro, et al. “538 Correlation Between Adalimumab Serum Levels and Remission After the Induction Phase in Crohn’s Disease Patients.” Gastroenterology, vol. 148, Apr. 2015, p. S-107. EBSCOhost, https://doi.org/10.1016/s0016-5085(15)30370-x.

APA

María Chaparro, Iván Guerra, Carlos Taxonera, Isabel Blazquez Gomez, Jesus M. Banales, Fernando Bermejo, Valle García-Sánchez, Isabel Vera, Luis Menchén, Belén Beltrán, Beatriz Benitez Garcia, Ignacio Marín-Jiménez, María Dolores Martín Arranz, Luis Bujanda, Patricia Aguilar-Melero, Rocío González Ferreiro, Joaquín Hinojosa, Laura Sempere, Marisa Iborra, … Manuel Barreiro-de Acosta. (2015). 538 Correlation Between Adalimumab Serum Levels and Remission After the Induction Phase in Crohn’s Disease Patients. Gastroenterology, 148, S-107. https://doi.org/10.1016/s0016-5085(15)30370-x

Chicago

María Chaparro, Iván Guerra, Carlos Taxonera, Isabel Blazquez Gomez, Jesus M. Banales, Fernando Bermejo, Valle García-Sánchez, et al. 2015. “538 Correlation Between Adalimumab Serum Levels and Remission After the Induction Phase in Crohn’s Disease Patients.” Gastroenterology 148 (April): S-107. doi:10.1016/s0016-5085(15)30370-x.